Absorption and bioeffects of an isoflavone-based supplementation in postmenopausal women

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 3, 2009, Pages 254-260

  Pampaloni, Barbara ^a   Bartolini, Silvia ^a   Bartolini, Elisa ^a   Ottanelli, Silva ^a   Masi, Laura ^a   Romani, Annalisa ^a   Tanini, Annalisa ^a   Vignolini, Pamela ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hot flushes; HPLC analysis; Isoflavones; Menopause; Phytoestrogens

Indexed keywords

DAIDZEIN; GENISTEIN; ISOFLAVONE;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG URINE LEVEL; ENDOMETRIUM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; INTERVIEW; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POSTMENOPAUSE; RATING SCALE; RELIABILITY; TABLET; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; VALIDATION STUDY;

EID: 76749086227     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: End of a tale? Annals of Medicine. 2005;37:1-16.
2. Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavalability. Am J Clin Nutr. 2004:79:727-47.
3. United States Department of Agriculture (USDA)- Iowa State University Database on the isoflavone contents of foods (1999) Nutrient data laboratory. Available at: http://www.ars.usda.gov Accessed September 10, 2007.
4. Fletcher RJ. Food sources of phyto-oestrogens and their precursor in Europe. Br J Nutr. 2003;89(Suppl. 1 ):S39-S43.
5. Morandi S, D'Agostina A, Ferrario F, et al. Isoflavone content of Italian soy food products and daily intakes of some specific classes of consumers. Eur Food ResTechnol. 2005;221:84-91.
6. Kloboska R, Klejdus B, Kokoska L, et al. Isoflavonoids in the solanaceae family. Polyphenols communications 2006, Winnipeg-Manitoba-Canada.
7. Mustonen EA, Tuori M, Saastamoinen I, et al. Equol content in plasma and milk of red clover fed cows. Winnipeg-Manitoba-Canada. Polyphenols communications 2006.
8. Yamaguchi M. Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. The pharmaceutical society of Japan. Yakugaku Zasshi. 2006;126(11 ):1117-1137.
9. Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol. 2005;94:499-518.
10. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone Daidzein: Exploring the relevance to human health. Exp Biol Med. 2005;230:155-170.
11. Cassidy A. Albertazzi P, Nielsen IL, et al. Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc. 2006;65:76-92.
12. Heinonen SM, Hoikkala A, Wahala K, et al. Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Biol. 2003;87(4-5):285-99.
13. King RA, Bursill DB. Plasma urinary and kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr. 1998;67:367-72.
14. De Pascual-Teresa S, Hallund J, Talbot D, et al. Absorption of isoflavones in humans: effects of food matrix and processing. J Nutr Biochem. J Nutr Biochem. 2006;17(4):257-64.
15. Anupongsanugool E, Teekachunhatean S, Rojanasthien N, et al. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin Pharmacol. 2005;5 (1):2.
16. Setchell KD, Brown NM, Desai PB, et al. Bioavalability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131 (Suppl 4):1362S-75S.
17. Cassidy A, Brown JE, Hawdon A, et al. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr. 2006; 136(1 ):45-51.
18. Setchell KDR, Brzezinski A, Brown NM, et al. Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women. J Agric Food Chem. 2005;53:1938-1944.
19. Bloedon LeAnne T. Robert JA, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002;76:1126-37.
20. Setchell KDR, Faughnan MS, Avades T, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77: 411-9.
21. Brandi ML. Natural and syntetic isoflavones in the prevention and treatment of chronic diseases. Calcif Tissue Int. 1997;61 Suppl 1:S5-8.
22. Anderson JJ, Garner SC. Phytoestrogens and bone. Baillieres Clin Endocrinol Metab. 1998;12(4):543-57.
23. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors α and β to the estrogen response element. J Agric Food Chem. 2003;51(26):7632-7635.
24. Kirk CJ, Harris RM, Wood DM, et al. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by distrupting the metabolism of endogenous oestrogens? Biochem Soc Trans. 2001;29(Pt 2):209-16.
25. Le Bail JC, Champavier Y, Chulia AJ, et al. Effects of phytoestrogens on aromatase, 3beta and 17 beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci. 2000;66 (14):1281-91.
26. Fotsis T, Pepper MS, Montesano R, et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab. 1998;12 (4):649-66.
27. Traganos F, Ardelt B, Halko N, et al. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res. 1992; 52(22):6200-8.
28. Weaver CM, Cheong JMK. Soy isoflavones and bone health: The relationship is still unclear. J Nutr. 2005;135:1243-1247.
29. Van Erp-Baart MA, Brants HA, Kiely M, et al. Isoflavone intake in four different European countries: the VENUS approach. Br J Nutr. 2003;89 Suppl 1:S25-30.
30. Ritchie MR, Cummings JH, Morton MS, et al. A newly constructed and validated isoflavones database for the assessment of total genistein and daidzein intake. Br J Nutr. 2006;95(1 ):204-13.
31. Ricketts ML, Moore DD, Banz WJ, et al. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem. 2005;16(6):321-30.
32. Miggiano GAD, Gagliardi L. Diet, nutrition and bone health. Clin Ter. 2005;156(1-2):47-56.
33. Potter SM, Baum JA, Teng HY, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998;68:1375S-137S.
34. Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational and dietary intervention studies. Am J Clin Nutr. 2003; 78 (suppl):593S-609S.
35. Bhakta D, Higgins CD, Sevak L, et al. Phyto-oestrogen intake and plasma concentrations in South Asian and native British women resident in England. Br J Nutr. 2006;95(6):1150-8.
36. Berrino F. Western diet and Alzheimer's disease. Epidemiol Prev. 2002;26(3):107-15.
37. Krebs EE, Ensrud KE, MacDonald R, et al. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol. 2004;104(4):824-36.
38. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29(1 ):25-31.
39. Pinkerton JV, Santen R. Use of alternatives to estrogen for treatment of menopause. Minerva Endocrinol. 2002;27(1 ):21 -41.
40. McGartland CP, Robson P, Murray LJ, et al. Fruit and vegetable consumption and bone mineral density: the Northern Ireland Young Hearts Project. Am J Nutr. 2004;80:1019-23.
41. Manach C, Morand C, Crespy V, et al. Ouercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett. 1998;426(3):331-6.
42. Frankie AA, Custer LJ, Wang W, et al. HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. P.S.E.B.M. 1998;217: 263-273
43. Società Italiana di Nutrizione Umana (1996) Livelli di Assunzione Raccomandati di Energia e Nutrienti per la Popolazione Italiana (LARN), S.I.N.U., Milan, Italy.
44. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr. 1999;129(3):758S-767S.
45. Sellmeyer DE, Stone KL, Sebastian A et al. A high ratio of dietary animal to vegetable protein increases in the rate of bone loss and the risk of fracture in postmenopausal women. Am J Clin Nutr. 2001;73 (1):118-122.
46. Barzel US, Massey LK. Excess dietary protein can adversely affect bone. J Nutr. 1998; 128:1051-1053
47. Cashman KD. Diet, nutrition, and bone health. J Nutr. 2007;137 (11 Suppl):2507S-2512S.
48. French MR, Thompson LU, Hawker GA. Validation of a phytoestrogen food frequency questionnaire with urinary concentrations of isoflavones and lignan metabolites in premenopausal women. J Am Coll Nutr. 2007;Vol.26, No.1:76-82.
49. Setchell KD, Faughnan MS, Avades T, et al.. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77 (2):411-9.
50. Howes JB, Howes LG. Content of isoflavone-containing preparations. MJA. 2002;176(3):135-136.
51. Wutteke W, Jarry H, Seidlova-Wuttke D. Isoflavones - safe food additives or dangerous drugs? Ageing Res Rev. 2007;6(2):150-88.
52. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. Am J Med. 2005;118(Suppl 12B):93-7.
53. Eden J. Phytoestrogens and the menopause. Baillieres Clin Endocrinol Metab. 1998;12(4):581-7. Review.
54. Sammartino A, Cirillo D, Mandato VD, et al. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy. J Endocrinol Invest. 2005;28(10 Suppl):80-4.
55. Usui T. Pharmeceutical prospects of phytoestrogens. Endocr J. 2006;53(1 ):7-20.
56. Tikkanen MJ, Wahala K, Ojala S, et al. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A. 1998;95(6):3106-10.
57. Simons LA, Von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol. 2000;85(11 ):1297-301.
58. Dixon RA. Phytoestrogens. Annu Rev Plant Biol. 2004;55:225-61.
59. Kronenbeig F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomised, controlled trials. Ann Intern Med. 2002;137:305-813.